Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing ...

Eli Lilly has turned to a biotechnology startup for help building ... to study STX-678 together with a so-called CDK4 ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Year to date, Eli Lilly’s shares have surged 36.6% compared with the industry’s 7.7% rise. Image Source: Zacks Investment Research An orally administered CDK4/6 inhibitor, Verzenio is approved ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... In the third quarter, Lilly's revenue from the breast cancer drug Verzenio increased by 32% year over year to $1.4 billion. Sales from the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...